Sorrento could be the next breakout stock. Find out why!
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is in the spotlight after receiving a “Buy” rating along with a $30 price target from Ram Selvaraju an analyst at H.C Wainwright, implying a nearly 275% upside from its current levels. We take a look at reasons for the...
